TRUMP’S BOLD MOVE: Psychedelics Fast-Tracked!

President Trump just unlocked a federal fast-track for ibogaine—a banned psychedelic veterans are secretly using abroad to beat PTSD—but will it save lives or unleash risks?

Story Snapshot

Trump signed executive order on April 18, 2026, directing FDA to expedite psychedelic reviews, focusing on ibogaine for PTSD and brain injuries.
Allots $50 million via HHS for state psychedelic programs while keeping ibogaine Schedule I.
Creates Right to Try pathways for patients, prioritizing veterans amid suicide crisis.
Combat veterans and conservatives embrace it despite safety concerns from unregulated foreign clinics.
Promises life-changing treatments but demands rigorous trials to prove effectiveness.

Executive Order Signing Details

President Donald Trump signed the executive order “Accelerating Medical Treatments for Serious Mental Illness” on April 18, 2026, in the Oval Office. Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan joined him. Trump announced historic reforms to speed access to psychedelic research and treatments. He highlighted ibogaine’s potential for veterans suffering severe mental illness and depression. The signing addressed the veteran suicide crisis directly.

Ibogaine’s Origins and Global Use

Ibogaine derives from an African shrub and treats depression, anxiety, addiction, PTSD, and brain trauma in clinical settings abroad. Americans travel to unregulated clinics in Mexico and the Caribbean for treatments lacking U.S. oversight. These facilities skip heart screening, monitoring protocols, and adverse event reporting. Domestic Schedule I status blocks research and use, forcing risky international trips. FDA already designated some psychedelics as Breakthrough Therapies showing promise.

Core Provisions of the Order

FDA Commissioner issues National Priority Vouchers to Breakthrough Therapy psychedelics, slashing review times. Right to Try Act pathways let eligible patients access ibogaine with DEA authorizations for doctors and researchers. HHS allocates $50 million from existing funds to state psychedelic programs via its Advanced Research Projects Agency for Health. HHS and FDA partner with VA and private sector to boost veteran trial participation and data sharing. Ibogaine stays Schedule I, no reclassification planned.

Trump administration views research as early-stage to test if ibogaine proves legitimate or mere hype. Officials stress advanced clinical trials ensure safety and effectiveness before wider use. Conservative lawmakers and combat veterans pushed this, embracing ibogaine despite serious safety risks. Facts align with common sense: prioritize warriors without rushing unproven drugs, upholding personal responsibility in treatment choices.

10. Trump signs order to research psychedelic used abroad to treat PTSD – CBS Newshttps://t.co/oMBwTjsY6d

11. Trump’s antipathy for Pope may have roots in childhood Protestant church – Guardian Russia

— Veritas News (@veritasfeed) April 18, 2026

Impacts on Veterans and Mental Health

Veterans gain priority access, tackling post-9/11 suicide rates through VA collaborations. Short-term, expedited reviews accelerate trials; Right to Try offers hope for treatment-resistant PTSD patients. Long-term, success could reshape paradigms for depression and addiction, reducing overseas clinic demand. States build programs with federal cash, standardizing protocols missing abroad. Pharmaceutical firms eye new markets; researchers secure funding boosts.